DENVER, April 18 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG), a
biopharmaceutical company focused on the discovery, development and
commercialization of small molecule therapeutics for the treatment of
cardiovascular disorders, today announced that it will report 2005
first quarter results the afternoon of Monday, May 2, 2005.
J. William Freytag, President and CEO, and other members of Myogen's
senior management will provide a company update and discuss results via
webcast and conference call on Monday, May 2, 2005 at 4:30 pm Eastern. To
access the live webcast, please log on to the company's website at
http://www.myogen.com and go to the Investor Relations section. Alternatively,
callers may participate in the conference call by dialing 800-218-8862
(domestic) or 303-262-2131 (international). Webcast and telephone replays of
the conference call will be available approximately two hours after the
completion of the call through Friday, May 20, 2005. Callers can access the
replay by dialing 800-405-2236 (domestic) or 303-590-3000 (international).
The passcode is 11028303#.
About Myogen
Myogen currently markets one product (Perfan(R) I.V.) in Europe for the
treatment of acute decompensated heart failure and has three product
candidates in late-stage clinical development: enoximone capsules for the
treatment of patients with advanced chronic heart failure, ambrisentan for the
treatment of patients with pulmonary arterial hypertension and darusentan for
the treatment of patients with resistant systolic hypertension. The company,
in collaboration with Novartis, also conducts a target and drug discovery
research program focused on the development of disease-modifying drugs for the
treatment of chronic heart failure and related cardiovascular disorders.
Please visit our website at http://www.myogen.com.
Safe Harbor Statement
The 2005 first quarter results press release and conference call will
contain forward-looking statements that involve significant risks and
uncertainties, including those that can be found in the "Risk Factors" section
of Myogen's Form 10-K for the year ended December 31, 2004 and in Myogen's
periodic reports on Form 10-Q and Form 8-K. Myogen is providing the
information contained in the release and conference call as of the date of the
release and does not undertake any obligation to update any forward-looking
statements as a result of new information, future events or otherwise. The
company cautions investors not to place undue reliance on the forward-looking
statements contained in the press release or the conference call. No
forward-looking statement can be guaranteed and actual events and results may
differ materially from those projected.
SOURCE Myogen, Inc.
 back to top
Related links:
http://www.myogen.com
CONTACT:
Derek K. Cole, Director, Investor Relations
of Myogen, Inc., +1-303-464-3986, derek.cole@myogen.com
|
